Today: 8 June 2026
Browse Category

NYSE:IAU 2 January 2026 - 10 February 2026

Gold price breaks $4,600 record; GLD ETF and gold stocks jump on Powell probe

Gold price breaks $4,600 record; GLD ETF and gold stocks jump on Powell probe

Gold prices hit a record $4,627.27 an ounce Monday, lifting SPDR Gold Shares 2.4% to $424.45 and sparking gains across gold-linked stocks. The dollar index slipped 0.2% as investors eyed Federal Reserve policy and the Powell investigation. CME FedWatch put the odds of steady rates in January at 95%. U.S. consumer price data is due Tuesday, with the Fed meeting Jan. 27-28.
12 January 2026
·······
Gold price rally lifts GLD stock in premarket as Fed cut bets grow, Venezuela in focus

Gold price rally lifts GLD stock in premarket as Fed cut bets grow, Venezuela in focus

SPDR Gold Shares (GLD) jumped $10.41, or 2.6%, to $408.76 in U.S. premarket trading Tuesday as spot gold hovered near highs after the U.S. captured Venezuelan President Nicolas Maduro. Traders cited safe-haven demand and rising bets on Federal Reserve rate cuts. The ISM manufacturing PMI fell to 47.9 in December, its lowest since October 2024. Other gold funds and miners also advanced before the bell.
6 January 2026
·········
Gold price stock today: GLD jumps nearly 2% in premarket as gold rebounds toward record highs

Gold price stock today: GLD jumps nearly 2% in premarket as gold rebounds toward record highs

SPDR Gold Shares (GLD) rose 1.9% to $404.00 in premarket trading, tracking a nearly 2% jump in spot gold to $4,397.66 an ounce. Gold hit a record $4,549.71 on Dec. 26 and gained 64% in 2025, its strongest year since 1979. Newmont climbed 2.8% premarket as gold and silver advanced. Investors await key U.S. jobs and inflation data next week for signals on Federal Reserve policy.
2 January 2026
·····

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop